US-India Leaders Summit: Paving the Way for Affordable Diabetes & Cancer Care in the US

India and the U.S. are witnessing a deepening of ties with a convergence of views on many issues. India is rapidly emerging as a preferred economic and technology partner for the US. India IT and pharma companies have made significant investments and have created jobs in the US. These investments signal a growing economic interdependence … Continue reading US-India Leaders Summit: Paving the Way for Affordable Diabetes & Cancer Care in the US

‘Patient-first, Science Based Regulatory Approaches for Insulins’

Dr. Sundar Ramanan, VP, Global Regulatory Affairs, Biocon, Presented at the U.S. FDA Public Hearing on Increasing Insulins Access Biocon Ltd. was among a handful of biopharmaceutical companies that presented at the U.S. Food and Drug Administration’s (FDA) public hearing “The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and … Continue reading ‘Patient-first, Science Based Regulatory Approaches for Insulins’

Biocon’s Differentiated Innovation Story Beginning to Pay Off

Biocon’s biopharma journey took off on a differentiated path fraught with challenges.  In the late 90’s when we started the prevailing business ethos in pharmaceutical sector favored a predictable and attractive ROCE (Return On Capital Employed) ventures based on chemically synthesized generic drugs. Biocon, however, chose to invest in developing biologic drugs based on recombinant … Continue reading Biocon’s Differentiated Innovation Story Beginning to Pay Off

We expect the momentum in the Biologics business to continue, says Biocon CFO

Biocon reported better-than-expected revenue and profit in the second quarter of FY19 on the back of good performance by its Biologics, Research Services and Small Molecules business segments. Siddharth Mittal, President (Finance) and CFO, spoke to by K Giriprakash and Venkatesh Ganesh of Hindu BusinessLine about the company’s results and prospects. Excerpts from the interview. … Continue reading We expect the momentum in the Biologics business to continue, says Biocon CFO

Kiran Mazumdar-Shaw felicitated by Government of Rajasthan, as the ‘Precious Daughter of India’

On September 28, 2018, the 4th Annual Healthcare Summit & Precious Daughters of India Awards was organised by National Health Mission, Department of Medical, Health & Family welfare, Government of Rajasthan in Jaipur. The event focused on highlighting the importance of Saving the Girl Child & honouring outstanding women as Daughters of India. Ms. Kiran … Continue reading Kiran Mazumdar-Shaw felicitated by Government of Rajasthan, as the ‘Precious Daughter of India’

Biocon’s Insulin Glargine Journey: Crossing a Key Milestone with EC Approval

As a credible, global insulins player, Biocon made sure-footed progress towards its mission of providing a high quality, affordable insulin analog for people with diabetes globally when the European Commission approved the biosimilar Insulin Glargine application submitted by its co-development partner Mylan. Biocon and Mylan are among the first few to receive approval for biosimilar … Continue reading Biocon’s Insulin Glargine Journey: Crossing a Key Milestone with EC Approval

Expanding Oncology Portfolio for the Benefit of Cancer Patients

We added another feather in our cap with the U.S. FDA approval of Fulphila™, biosimilar Pegfilgrastim co-developed with our partner Mylan. Fulphila™ is the first FDA-approved biosimilar Pegfilgrastim and the second biosimilar from Biocon and Mylan’s joint portfolio approved in the U.S. Pegfilgrastim is a long-lasting, pegylated form of recombinant granulocyte colony-stimulating factor that is … Continue reading Expanding Oncology Portfolio for the Benefit of Cancer Patients

Biocon’s Trastuzumab Journey: First biosimilar from India to be approved by U.S. FDA

December 2017 was a defining moment in our biosimilars journey when Biocon and partner Mylan became the first companies globally to receive U.S. Food and Drug Administration (FDA) approval for biosimilar Trastuzumab. Ogivri™ (trastuzumab-dkst) was the first biosimilar from Mylan and Biocon’s joint portfolio approved in the U.S., and it made us the first Indian … Continue reading Biocon’s Trastuzumab Journey: First biosimilar from India to be approved by U.S. FDA